Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. [PDF]
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel.
Hoffman-Censits, Jean, Patel, Sheel
core +3 more sources
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study [PDF]
BackgroundThis phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.MethodsPatients were enrolled in four cohorts: MM-302 ...
Adiwijaya, Bambang S +14 more
core +2 more sources
OBJECTIVES We aimed to describe the current time-to-positivity (TTP) of blood cultures in individuals with onco-haematological diseases with febrile neutropenia.
P. Puerta-Alcalde +13 more
semanticscholar +1 more source
Screening of the central nervous system in children with invasive pulmonary aspergillosis [PDF]
Peer reviewedPublisher ...
Broenen, Emmi +5 more
core +2 more sources
Introduction: Febrile neutropenia is a life-threatening condition that is the most common oncological emergency, especially in cases of hematological cancer. Knowledge related to this condition can accelerate treatment and reduce mortality. The danger of
Agus Suryaman
doaj +1 more source
Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
Background. Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10-20%) of febrile neutropenia.
Kukec Renata Rezonja +5 more
doaj +1 more source
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. [PDF]
Lessons learnedThe safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group.The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients ...
Bendell, Johanna +5 more
core +1 more source
BACKGROUND People with cancer with febrile neutropenia are at risk of severe infections and mortality and are thus treated empirically with broad-spectrum antibiotic therapy.
A. Stern +5 more
semanticscholar +1 more source
Capnocytophaga sputigena bacteremia in a neutropenic host
Capnocytophaga species belong to the oral microbiota but are not a common cause of infection in febrile neutropenia. Nevertheless, neutropenia can cause bacteremia associated with mucositis, with lower rates of mortality.
Ramírez Isabel
doaj +1 more source
Thrombin generation in children with febrile neutropenia
Background. Febrile neutropenia (FN) is a common and serious complication in patients with leukemia. Hemostasis and inflammation are two interrelated systems in response to infection.
Ayça Koca Yozgat +6 more
doaj +1 more source

